Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01311687 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
NCT01311687 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 455 participants.
The verdict
NCT01311687, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
Study Summary
The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2011-03-11 |
| Est. Completion | 2017-08-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01311687
The ClinicalTrials.gov registry entry for NCT01311687 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01311687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01311687 about?
NCT01311687 is a clinical study titled "A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study". The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma.
What is the current status of trial NCT01311687?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2011-03-11. Estimated completion is 2017-08-29.
What interventions are being tested in trial NCT01311687?
The interventions under investigation include: Dexamethasone (DRUG), pomalidomide (DRUG).
Who is sponsoring clinical trial NCT01311687?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.